Stocks and Investing
by (remove) : David Lewis
RSSJSONXMLCSV
Stocks and Investing
by (remove) : David Lewis
RSSJSONXMLCSV
Thu, October 19, 2023
Fri, July 21, 2023
Tue, October 11, 2022
Fri, July 15, 2022
Fri, May 6, 2022
Fri, April 29, 2022
Mon, April 11, 2022
Mon, March 28, 2022
Fri, February 25, 2022
Fri, February 18, 2022
Fri, February 4, 2022
Fri, January 7, 2022
Fri, October 29, 2021
Mon, August 9, 2021
Fri, May 7, 2021
Wed, May 5, 2021
Fri, April 30, 2021
Wed, April 28, 2021
Wed, April 21, 2021
Mon, April 19, 2021
Mon, March 8, 2021
Thu, March 4, 2021
Thu, February 25, 2021
Mon, February 8, 2021
Thu, January 28, 2021

David Lewis Maintained (ABT) at Hold with Decreased Target to $107 on, Oct 19th, 2023


Published on 2024-10-28 06:58:37 - WOPRAI, David Lewis
  Print publication without navigation


David Lewis of Morgan Stanley, Maintained "Abbott Laboratories" (ABT) at Hold with Decreased Target from $112 to $107 on, Oct 19th, 2023.

David has made no other calls on ABT in the last 4 months.



There are 3 other peers that have a rating on ABT. Out of the 3 peers that are also analyzing ABT, 2 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Mike Polark of "Wolfe Research" Upgraded from Sell to Hold on, Friday, July 21st, 2023
  • Anthony Petrone of "Mizuho" Initiated at Hold with Increased Target to $115 on, Friday, July 21st, 2023


This is the rating of the analyst that currently disagrees with David


  • Joanne Wuensch of "Citigroup" Maintained at Strong Buy with Decreased Target to $122 on, Monday, October 2nd, 2023
Contributing Sources